Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Summary

This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with bortezomib and to see how well they work in treating patients with relapsed multiple myeloma. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer cells.

Timeline

Start

2005-08

Primary completion

2007-02

Completion

—

Drugs

Indications